%0 Journal Article
%T Unexpected Synergy Reveals New Therapeutic Strategy in SCLC
%J -
%D 2019
%R https://doi.org/10.1016/j.tips.2019.03.005
%X DNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues ( Cancer Discov. 2019; https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC
%U https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(19)30063-X